Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 11/20 | 1.00 |
| ▸ | DRD4 | P21917 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14974690 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL10570451 | 0.97 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL251472 | 0.96 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL10574132 | 0.94 | DRD2 (0.95) | DRD2DRD3DRD4 | |
| SCHEMBL8078 | 0.92 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL11333597 | 0.91 | DRD2 (0.88) | DRD2DRD3DRD4 | |
| SCHEMBL10573201 | 0.89 | DRD2 (0.95) | DRD2DRD3DRD4 | |
| SCHEMBL250675 | 0.89 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL13532795 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4 | |
| SCHEMBL252031 | 0.87 | DRD2 (1.00) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | claimed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | claimed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | DRD2 26/4885DRD3 64/4885DRD4 38/4885 |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | DRD2 1/4885DRD3 12/4885DRD4 41/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885DRD3 432/4885DRD4 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.